TECA hybrid artificial liver support system in treatment of acute liver failure
- PMID: 11854910
- PMCID: PMC4695603
- DOI: 10.3748/wjg.v7.i6.826
TECA hybrid artificial liver support system in treatment of acute liver failure
Abstract
Aim: To assess the efficacy and safety of TECA type hybrid artificial liver support system (TECA-HALSS) in providing liver function of detoxification, metabolism and physiology by treating the patients with acute liver failure (ALF).
Methods: The porcine liver cells (1-2) x 10(10) were separated from the Chinese small swine and cultured in the bioreactor of TECA-BALSS at 37.0 degrees C and circulated through the outer space of the hollow fiber tubes in BALSS. The six liver failure patients with various degree of hepatic coma were treated by TECA-HALSS and with conventional medicines. The venous plasma of the patients was separated by a plasma separator and treated by charcoal adsorbent or plasma exchange. The plasma circulated through the inner space of the hollow fiber tubes of BALSS and mixed with the patients' blood cells and flew back to their blood circulation. Some small molecular weight substances were exchanged between the plasma and porcine liver cells. Each treatment lasted 6.0-7.0 h. Physiological and biochemical parameters were measured before,during and after the treatment.
Results: The average of porcine liver cells was (1.0-3.0) x 10(10) obtained from each swine liver using our modified enzymatic digestion method. The survival rate of the cells was 85%-93% by trypan blue stain and AO/PI fluorescent stain. After cultured in TECA-BALSS bioreactor for 6 h, the survival rate of cells still remained 70%-85%. At the end of TECA-HALSS treatment, the levels of plasma NH(3), ALT, TB and DB were significantly decreased. The patients who were in the state of drowsiness or coma before the treatment improved their appetite significantly and regained consciousness, some patients resumed light physical work on a short period after the treatment. One to two days after the treatment, the ratio of PTA increased warkedly. During the treatment, the heart rates, blood pressure, respiration condition and serum electrolytes (K(+), Na(+) and Cl(-)) were stable without thrombosis and bleeding in all the six patients.
Conclusion: TECA-HALSS treatment could be a rapid, safe and efficacious method to provide temporary liver support for patients with ALF.
Similar articles
-
Experimental research on TECA-I bioartificial liver support system to treat canines with acute liver failure.World J Gastroenterol. 2001 Oct;7(5):706-9. doi: 10.3748/wjg.v7.i5.706. World J Gastroenterol. 2001. PMID: 11819859 Free PMC article.
-
Study of severe hepatitis treated with a hybrid artificial liver support system.Int J Artif Organs. 2003 Jun;26(6):507-13. doi: 10.1177/039139880302600609. Int J Artif Organs. 2003. PMID: 12866656
-
Hybrid artificial liver support system for treatment of severe liver failure.World J Gastroenterol. 2005 Feb 14;11(6):890-4. doi: 10.3748/wjg.v11.i6.890. World J Gastroenterol. 2005. PMID: 15682488 Free PMC article.
-
[Liver support systems today].Orv Hetil. 2009 Dec 20;150(51):2299-307. doi: 10.1556/OH.2009.28769. Orv Hetil. 2009. PMID: 19995693 Review. Hungarian.
-
Bioartificial liver support.J Hepatobiliary Pancreat Surg. 2001;8(1):1-15. doi: 10.1007/s005340170045. J Hepatobiliary Pancreat Surg. 2001. PMID: 11294283 Review.
Cited by
-
Establishment of a risk assessment score for deep vein thrombosis after artificial liver support system treatment.World J Clin Cases. 2021 Nov 6;9(31):9406-9416. doi: 10.12998/wjcc.v9.i31.9406. World J Clin Cases. 2021. PMID: 34877276 Free PMC article.
-
Liver Cell Culture Devices.Cell Med. 2010 Jul 1;1(1):55-70. doi: 10.3727/215517910X519274. eCollection 2010. Cell Med. 2010. PMID: 26998397 Free PMC article.
-
End-stage liver failure: filling the treatment gap at the intensive care unit.J Artif Organs. 2020 Jun;23(2):113-123. doi: 10.1007/s10047-019-01133-3. Epub 2019 Sep 18. J Artif Organs. 2020. PMID: 31535298 Free PMC article. Review.
-
Clinical usefulness of measuring red blood cell distribution width in patients with hepatitis B.PLoS One. 2012;7(5):e37644. doi: 10.1371/journal.pone.0037644. Epub 2012 May 23. PLoS One. 2012. PMID: 22649548 Free PMC article.
-
Effects of hemoperfusion adsorption and/or plasma exchange in treatment of severe viral hepatitis: a comparative study.World J Gastroenterol. 2004 Apr 15;10(8):1218-21. doi: 10.3748/wjg.v10.i8.1218. World J Gastroenterol. 2004. PMID: 15069730 Free PMC article. Clinical Trial.
References
-
- Zhang SC, Dai Q, Wang JY, He BM, Zhou K. Gut-derived endotoxemia: one of the factors leading to production of cytokines in liver diseases. World J Gastroenterol. 2000;6(Suppl 3):16.
-
- Li JY, Huang Y, Lin MF. Clinical evaluation of several tumor markers in the diagnosis of primary hepatic cancer. World J Gastroenterol. 2000;6(Suppl 3):39.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous